Reviewing Aimmune Therapeutics Inc. (AIMT)’s and Achaogen Inc. (NASDAQ:AKAO)’s results

Aimmune Therapeutics Inc. (NASDAQ:AIMT) and Achaogen Inc. (NASDAQ:AKAO) compete against each other in the Biotechnology sector. We will compare them and contrast their analyst recommendations, profitability, institutional ownership, risk, dividends, earnings and valuation.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Aimmune Therapeutics Inc. N/A 0.00 210.75M -3.00 0.00
Achaogen Inc. 8.73M 1.37 186.51M -3.96 0.00

Table 1 highlights Aimmune Therapeutics Inc. and Achaogen Inc.’s gross revenue, earnings per share and valuation.

Profitability

Table 2 provides us Aimmune Therapeutics Inc. and Achaogen Inc.’s return on equity, return on assets and net margins.

Net Margins Return on Equity Return on Assets
Aimmune Therapeutics Inc. 0.00% -67.2% -59.2%
Achaogen Inc. -2,136.43% -227.2% -113.1%

Volatility and Risk

A -0.13 beta means Aimmune Therapeutics Inc.’s volatility is 113.00% less than S&P 500’s volatility. Achaogen Inc.’s 16.00% less volatile than S&P 500 volatility due to the company’s 0.84 beta.

Liquidity

The Current Ratio and Quick Ratio of Aimmune Therapeutics Inc. are 7 and 7 respectively. Its competitor Achaogen Inc.’s Current Ratio is 2.5 and its Quick Ratio is 2.5. Aimmune Therapeutics Inc. can pay off short and long-term obligations better than Achaogen Inc.

Analyst Recommendations

Aimmune Therapeutics Inc. and Achaogen Inc. Ratings and Recommendations are available on the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Aimmune Therapeutics Inc. 0 0 0 0.00
Achaogen Inc. 0 6 0 2.00

Competitively Achaogen Inc. has an average price target of $2.75, with potential upside of 1,370.59%.

Institutional and Insider Ownership

The shares of both Aimmune Therapeutics Inc. and Achaogen Inc. are owned by institutional investors at 83.3% and 36.2% respectively. Insiders owned 0.1% of Aimmune Therapeutics Inc. shares. Insiders Competitively, owned 16.9% of Achaogen Inc. shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Aimmune Therapeutics Inc. 2.14% 5.36% 0.16% -11.91% -24.45% 3.6%
Achaogen Inc. -5.41% -49.38% -57.77% -85.3% -92.67% -37.85%

For the past year Aimmune Therapeutics Inc. has 3.6% stronger performance while Achaogen Inc. has -37.85% weaker performance.

Summary

Aimmune Therapeutics Inc. beats Achaogen Inc. on 6 of the 10 factors.

Aimmune Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies in the United States and Europe. Its lead Characterized Oral Desensitization ImmunoTherapy product candidate is AR101, an investigational biologic for the treatment of patients with peanut allergy. Aimmune Therapeutics, Inc. has strategic collaboration with an affiliate of Nestle Health Science US Holdings, Inc. for the advancement of food allergy therapeutics. The company was formerly known as Allergen Research Corporation and changed its name to Aimmune Therapeutics, Inc. in May 2015. The company was founded in 2011 and is headquartered in Brisbane, California.

Achaogen, Inc., a late-stage biopharmaceutical company, discovers, develops, and commercializes antibacterials to treat multi-drug resistant (MDR) gram-negative infections in the United States. The company is principally developing plazomicin, which is in Phase III clinical trial for the treatment of serious bacterial infections, including urinary tract infections, blood stream infections, and other infections due to MDR Enterobacteriaceae comprising carbapenem-resistant Enterobacteriaceae. It is also involved in the research and development of antipseudomonal LpxC inhibitor compounds for the treatment of bacterial infections; and therapeutic antibody discovery program. The company has license and collaboration agreements with Thermo Fisher Scientific, Inc. to develop and commercialize an assay to to enable patients to receive safe and efficacious doses of plazomicin; Crystal Biosciences, Inc. to discover monoclonal antibodies against multiple targets; Ionis Pharmaceuticals, Inc. for certain patents relating to aminoglycoside antibacterial compounds and related know-how to develop and commercialize certain novel aminoglycoside antibacterial compounds; and Hovione Limited to manufacture the active pharmaceutical ingredient for plazomicin. The company was incorporated in 2002 and is based in South San Francisco, California.